United Therapeutics Corporation (UTHR)
USD 278.91
(-4.63%)
USD 278.91
(-4.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 885.1 Million USD | 9.29% |
| 2022 | 809.9 Million USD | -19.58% |
| 2021 | 1 Billion USD | 28.85% |
| 2020 | 781.6 Million USD | -48.54% |
| 2019 | 1.51 Billion USD | 143.51% |
| 2018 | 623.7 Million USD | 4.88% |
| 2017 | 594.7 Million USD | 28.06% |
| 2016 | 464.4 Million USD | -33.44% |
| 2015 | 697.71 Million USD | 11.84% |
| 2014 | 623.83 Million USD | -10.03% |
| 2013 | 693.35 Million USD | 84.83% |
| 2012 | 375.13 Million USD | 11.48% |
| 2011 | 336.49 Million USD | -8.15% |
| 2010 | 366.36 Million USD | 22.72% |
| 2009 | 298.52 Million USD | -10.48% |
| 2008 | 333.48 Million USD | 82.85% |
| 2007 | 182.37 Million USD | 60.51% |
| 2006 | 113.62 Million USD | 87.16% |
| 2005 | 60.7 Million USD | 16.45% |
| 2004 | 52.13 Million USD | -10.25% |
| 2003 | 58.08 Million USD | 36.13% |
| 2002 | 42.66 Million USD | -13.86% |
| 2001 | 49.53 Million USD | -39.48% |
| 2000 | 81.84 Million USD | 137.92% |
| 1999 | 34.4 Million USD | 156.72% |
| 1998 | 13.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 257.6 Million USD | 1.73% |
| 2024 Q2 | 317.2 Million USD | 27.65% |
| 2024 Q1 | 248.5 Million USD | -12.38% |
| 2023 Q2 | 219 Million USD | 28.67% |
| 2023 Q3 | 212.3 Million USD | -3.06% |
| 2023 Q4 | 283.6 Million USD | 33.58% |
| 2023 FY | 885.1 Million USD | 9.29% |
| 2023 Q1 | 170.2 Million USD | -34.54% |
| 2022 Q1 | 148 Million USD | -29.79% |
| 2022 FY | 809.9 Million USD | -19.58% |
| 2022 Q4 | 260 Million USD | 58.05% |
| 2022 Q3 | 164.5 Million USD | -30.12% |
| 2022 Q2 | 235.4 Million USD | 59.05% |
| 2021 Q4 | 210.8 Million USD | 11.95% |
| 2021 Q2 | 187.1 Million USD | -55.55% |
| 2021 FY | 1 Billion USD | 28.85% |
| 2021 Q3 | 188.3 Million USD | 0.64% |
| 2021 Q1 | 420.9 Million USD | 47.79% |
| 2020 Q2 | 195.6 Million USD | 17.69% |
| 2020 Q4 | 284.8 Million USD | 110.96% |
| 2020 Q3 | 135 Million USD | -30.98% |
| 2020 FY | 781.6 Million USD | -48.54% |
| 2020 Q1 | 166.2 Million USD | -24.04% |
| 2019 Q1 | 989.4 Million USD | 353.85% |
| 2019 FY | 1.51 Billion USD | 143.51% |
| 2019 Q2 | 125.5 Million USD | -87.32% |
| 2019 Q3 | 185.1 Million USD | 47.49% |
| 2019 Q4 | 218.8 Million USD | 18.21% |
| 2018 Q3 | 211.2 Million USD | 27.69% |
| 2018 FY | 623.7 Million USD | 4.88% |
| 2018 Q1 | 29.1 Million USD | -89.33% |
| 2018 Q2 | 165.4 Million USD | 468.38% |
| 2018 Q4 | 218 Million USD | 3.22% |
| 2017 Q2 | 127.2 Million USD | 37.37% |
| 2017 Q4 | 272.7 Million USD | 166.83% |
| 2017 FY | 594.7 Million USD | 28.06% |
| 2017 Q1 | 92.6 Million USD | -55.14% |
| 2017 Q3 | 102.2 Million USD | -19.65% |
| 2016 Q4 | 206.4 Million USD | 41.37% |
| 2016 Q2 | 107.4 Million USD | 2234.78% |
| 2016 Q1 | 4.6 Million USD | -97.95% |
| 2016 FY | 464.4 Million USD | -33.44% |
| 2016 Q3 | 146 Million USD | 35.94% |
| 2015 Q3 | -7.74 Million USD | -104.86% |
| 2015 FY | 697.71 Million USD | 11.84% |
| 2015 Q4 | 224.5 Million USD | 2997.26% |
| 2015 Q2 | 159.39 Million USD | -50.43% |
| 2015 Q1 | 321.55 Million USD | 111.53% |
| 2014 Q1 | 42.66 Million USD | -84.69% |
| 2014 Q3 | 321.38 Million USD | 198.2% |
| 2014 Q4 | 152.01 Million USD | -52.7% |
| 2014 Q2 | 107.77 Million USD | 152.61% |
| 2014 FY | 623.83 Million USD | -10.03% |
| 2013 Q1 | 121.78 Million USD | 57.04% |
| 2013 FY | 693.35 Million USD | 84.83% |
| 2013 Q4 | 278.73 Million USD | 67.04% |
| 2013 Q3 | 166.86 Million USD | 32.45% |
| 2013 Q2 | 125.98 Million USD | 3.45% |
| 2012 FY | 375.13 Million USD | 11.48% |
| 2012 Q3 | 133.78 Million USD | 48.06% |
| 2012 Q1 | 73.44 Million USD | -30.93% |
| 2012 Q4 | 77.54 Million USD | -42.03% |
| 2012 Q2 | 90.35 Million USD | 23.03% |
| 2011 Q4 | 106.34 Million USD | 39.76% |
| 2011 Q2 | 26.93 Million USD | -74.89% |
| 2011 Q3 | 76.08 Million USD | 182.5% |
| 2011 FY | 336.49 Million USD | -8.15% |
| 2011 Q1 | 107.26 Million USD | -21.85% |
| 2010 Q2 | 59.98 Million USD | -26.63% |
| 2010 Q1 | 81.74 Million USD | -16.25% |
| 2010 Q3 | 87.38 Million USD | 45.68% |
| 2010 Q4 | 137.25 Million USD | 57.08% |
| 2010 FY | 366.36 Million USD | 22.72% |
| 2009 FY | 298.52 Million USD | -10.48% |
| 2009 Q4 | 97.6 Million USD | 34.22% |
| 2009 Q3 | 72.72 Million USD | -6.79% |
| 2009 Q2 | 78.01 Million USD | 55.48% |
| 2009 Q1 | 50.17 Million USD | -75.11% |
| 2008 Q2 | 42.23 Million USD | 4.52% |
| 2008 Q3 | 49.23 Million USD | 16.57% |
| 2008 Q4 | 201.61 Million USD | 309.53% |
| 2008 FY | 333.48 Million USD | 82.85% |
| 2008 Q1 | 40.4 Million USD | -34.76% |
| 2007 Q2 | 38.44 Million USD | -11.17% |
| 2007 Q4 | 61.93 Million USD | 59.95% |
| 2007 Q3 | 38.72 Million USD | 0.72% |
| 2007 Q1 | 43.27 Million USD | 15.33% |
| 2007 FY | 182.37 Million USD | 60.51% |
| 2006 Q3 | 24.81 Million USD | 1.33% |
| 2006 Q4 | 37.52 Million USD | 51.25% |
| 2006 FY | 113.62 Million USD | 87.16% |
| 2006 Q1 | 26.8 Million USD | 66.14% |
| 2006 Q2 | 24.48 Million USD | -8.65% |
| 2005 Q3 | 15.04 Million USD | -4.3% |
| 2005 FY | 60.7 Million USD | 16.45% |
| 2005 Q1 | 13.81 Million USD | 5.87% |
| 2005 Q2 | 15.71 Million USD | 13.8% |
| 2005 Q4 | 16.13 Million USD | 7.25% |
| 2004 FY | 52.13 Million USD | -10.25% |
| 2004 Q4 | 13.04 Million USD | 7.5% |
| 2004 Q3 | 12.13 Million USD | -4.32% |
| 2004 Q2 | 12.68 Million USD | -11.05% |
| 2004 Q1 | 14.26 Million USD | -9.93% |
| 2003 FY | 58.08 Million USD | 36.13% |
| 2003 Q4 | 15.83 Million USD | 5.38% |
| 2003 Q3 | 15.02 Million USD | 1.62% |
| 2003 Q2 | 14.78 Million USD | 18.84% |
| 2003 Q1 | 12.44 Million USD | -8.77% |
| 2002 Q2 | 11.03 Million USD | 44.92% |
| 2002 FY | 42.66 Million USD | -13.86% |
| 2002 Q4 | 13.63 Million USD | 31.25% |
| 2002 Q3 | 10.39 Million USD | -5.8% |
| 2002 Q1 | 7.61 Million USD | -26.7% |
| 2001 Q3 | 12.35 Million USD | -8.91% |
| 2001 Q2 | 13.56 Million USD | 2.49% |
| 2001 FY | 49.53 Million USD | -39.48% |
| 2001 Q1 | 13.23 Million USD | -57.51% |
| 2001 Q4 | 10.38 Million USD | -15.95% |
| 2000 Q3 | 10.57 Million USD | -65.52% |
| 2000 Q4 | 31.14 Million USD | 194.55% |
| 2000 FY | 81.84 Million USD | 137.92% |
| 2000 Q1 | 9.45 Million USD | 13.9% |
| 2000 Q2 | 30.66 Million USD | 224.39% |
| 1999 Q2 | 6.3 Million USD | -49.19% |
| 1999 FY | 34.4 Million USD | 156.72% |
| 1999 Q4 | 8.3 Million USD | 15.28% |
| 1999 Q1 | 12.4 Million USD | 0.0% |
| 1999 Q3 | 7.2 Million USD | 14.29% |
| 1998 FY | 13.4 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -221.583% |
| Alkermes plc | 996.24 Million USD | 11.156% |
| Agenus Inc. | 78.18 Million USD | -1032.088% |
| Aptorum Group Limited | 10.56 Thousand USD | -8376769.203% |
| Ardelyx, Inc. | 169.93 Million USD | -420.84% |
| Dyadic International, Inc. | 9.15 Million USD | -9570.375% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -3877.441% |
| Lantern Pharma Inc. | 17.87 Million USD | -4850.897% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -13047.762% |
| Novavax, Inc. | 779.12 Million USD | -13.602% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -991.88% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -976.816% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -4458.021% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -2889.597% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -1566.027% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -132.617% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3541.397% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -2237.268% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -2776.41% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -944.785% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -4970.172% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -425.481% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -2605.487% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -453.925% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 50.829% |
| AlloVir, Inc. | 180.93 Million USD | -389.187% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -98.57% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -2881.942% |
| Bicycle Therapeutics plc | 216.92 Million USD | -308.027% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -414.886% |
| ChromaDex Corporation | 56.37 Million USD | -1469.911% |
| Chimerix, Inc. | 93.38 Million USD | -847.756% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -6263.212% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -487.966% |
| CRISPR Therapeutics AG | 463.49 Million USD | -90.963% |
| Precision BioSciences, Inc. | 92.46 Million USD | -857.248% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -248.404% |
| Fortress Biotech, Inc. | 200.19 Million USD | -342.119% |
| Fortress Biotech, Inc. | 200.19 Million USD | -342.119% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -2602.926% |
| ImmuCell Corporation | 9.61 Million USD | -9103.147% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -460.85% |
| Immix Biopharma, Inc. | 16.14 Million USD | -5383.513% |
| Incyte Corporation | 1.19 Billion USD | 25.653% |
| Innoviva, Inc. | 132.15 Million USD | -569.749% |
| IO Biotech, Inc. | 91.44 Million USD | -867.925% |
| Jaguar Health, Inc. | 42.01 Million USD | -2006.629% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -422.871% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -949.654% |
| ContextLogic Inc. | 387 Million USD | -128.708% |
| MiMedx Group, Inc. | 229.72 Million USD | -285.283% |
| MEI Pharma, Inc. | 34.78 Million USD | -2444.488% |
| NextCure, Inc. | 67.63 Million USD | -1208.603% |
| Onconetix, Inc. | 34.9 Million USD | -2435.563% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -6844.139% |
| Opthea Limited | 191.96 Million USD | -361.068% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -32066.915% |
| Vaxcyte, Inc. | 468.04 Million USD | -89.107% |
| PDS Biotechnology Corporation | 43.04 Million USD | -1956.209% |
| Precigen, Inc. | 84.18 Million USD | -951.425% |
| Pharming Group N.V. | 225.49 Million USD | -292.521% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -427.388% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -1119.717% |
| PureTech Health plc | 144.59 Million USD | -512.115% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -579.472% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -261.032% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -3541.397% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -287.047% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -2768.207% |
| Acelyrin, Inc. | 422.06 Million USD | -109.708% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -6864333.07% |
| Summit Therapeutics Inc. | 87.68 Million USD | -909.397% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -2288.032% |
| Senti Biosciences, Inc. | 94.7 Million USD | -834.586% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -616.373% |
| Elevation Oncology, Inc. | 45.44 Million USD | -1847.629% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -2903.495% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -22352.796% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -569.643% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -2496.743% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -10373.317% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -388.194% |
| Seer, Inc. | 110.49 Million USD | -701.068% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -1153.789% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -846.854% |
| ESSA Pharma Inc. | 32.13 Million USD | -2654.395% |
| GlycoMimetics, Inc. | 39.28 Million USD | -2153.006% |
| GT Biopharma, Inc. | 13.57 Million USD | -6419.593% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -302.629% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -340.096% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -241.178% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -1459.4% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -1536.649% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -8806.537% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -119.321% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -4575.894% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -1646.0% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -240.87% |
| Aptose Biosciences Inc. | 52.35 Million USD | -1590.542% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -6042.103% |
| Soligenix, Inc. | 7.79 Million USD | -11254.349% |
| Century Therapeutics, Inc. | 56.07 Million USD | -1478.534% |
| Kura Oncology, Inc. | 165.8 Million USD | -433.823% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -672.966% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -10539.5% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -35565.945% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -721.835% |
| Autolus Therapeutics plc | 196.72 Million USD | -349.915% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -945.513% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -660.049% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -4466.373% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -175.083% |
| GRI Bio, Inc. | 11.33 Million USD | -7712.004% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -12444.466% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -574.655% |
| IGM Biosciences, Inc. | 265.59 Million USD | -233.257% |
| INmune Bio, Inc. | 29.89 Million USD | -2860.597% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -412.941% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2095.498% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -5439.02% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -5522.698% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -1325.328% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -723.18% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -221.046% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -193.613% |
| Verastem, Inc. | 92.08 Million USD | -861.188% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -4833.943% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -376.565% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -629.035% |
| Histogen Inc. | 14.27 Million USD | -6101.654% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -5415.28% |
| Surrozen, Inc. | 18.55 Million USD | -4671.429% |
| Organovo Holdings, Inc. | 14.91 Million USD | -5834.294% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -17288.192% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -1383.246% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -3351.086% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -1782.951% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -11495.941% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -396.868% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -1726.909% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -261.259% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -5659.905% |
| Apollomics, Inc. | 54.14 Million USD | -1534.836% |
| Amarin Corporation plc | 272.35 Million USD | -224.978% |
| Mesoblast Limited | 5.9 Million USD | -14896.611% |
| Turnstone Biologics Corp. | 78.33 Million USD | -1029.848% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -262.565% |
| Synaptogenix, Inc. | 8.31 Million USD | -10546.085% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -5968.148% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -249.764% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -2555.56% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -9922.381% |
| Exelixis, Inc. | 1.58 Billion USD | 44.22% |
| Better Therapeutics, Inc. | 38.26 Million USD | -2213.261% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -281.426% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -3.496% |
| NLS Pharmaceutics AG | 11.8 Million USD | -7396.36% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -10906.097% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -2851.022% |
| Gritstone bio, Inc. | 148.37 Million USD | -496.533% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1185.343% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -5310.075% |
| Avid Bioservices, Inc. | 25.99 Million USD | -3304.755% |
| Insmed Incorporated | 949.26 Million USD | 6.759% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -5541.249% |
| MediWound Ltd. | 18.86 Million USD | -4591.011% |
| OmniAb, Inc. | 83.89 Million USD | -955.009% |
| Alector, Inc. | 248.8 Million USD | -255.745% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -277.751% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -1593.939% |
| Zai Lab Limited | 547.47 Million USD | -61.669% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -122.022% |
| Aura Biosciences, Inc. | 84.99 Million USD | -941.404% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -258.14% |
| Immunic, Inc. | 99.22 Million USD | -792.031% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -456.625% |
| Veracyte, Inc. | 357.93 Million USD | -147.281% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 90.183% |
| FibroGen, Inc. | 398.11 Million USD | -122.324% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -6128.712% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -12749.983% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -12321.18% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 72.813% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -3320.941% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -179.614% |
| TG Therapeutics, Inc. | 198.47 Million USD | -345.95% |
| Galecto, Inc. | 35.62 Million USD | -2384.352% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -2075.281% |
| Fortrea Holdings Inc. | 457.3 Million USD | -93.549% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -1530.679% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -2964.963% |
| XBiotech Inc. | 37.51 Million USD | -2259.637% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1185.343% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -4186.406% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -523.042% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -793.364% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -699.433% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 7.634% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -2968.469% |
| Vaxxinity, Inc. | 56.05 Million USD | -1479.098% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -105.531% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -3867.579% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -698.344% |
| NexImmune, Inc. | 28.16 Million USD | -3042.273% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -15902.682% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -4846.762% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 68.561% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -3376.57% |
| Scopus BioPharma Inc. | 11.71 Million USD | -7455.35% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -596.589% |
| Ainos, Inc. | 12.95 Million USD | -6733.344% |
| Pluri Inc. | 22.48 Million USD | -3837.278% |
| Prothena Corporation plc | 282.4 Million USD | -213.414% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -342.501% |
| Celularity Inc. | 215.05 Million USD | -311.563% |
| Rallybio Corporation | 78.93 Million USD | -1021.345% |
| Cue Biopharma, Inc. | 19.54 Million USD | -4429.219% |
| MeiraGTx Holdings plc | 151.07 Million USD | -485.856% |
| Omeros Corporation | 94.75 Million USD | -834.133% |
| Humacyte, Inc. | 23.49 Million USD | -3666.864% |
| Immunocore Holdings plc | 308.04 Million USD | -187.333% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -26009.145% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -918.937% |
| Blueprint Medicines Corporation | 722.86 Million USD | -22.444% |
| CalciMedica, Inc. | 21.81 Million USD | -3956.928% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -1085.508% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -451.327% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -416.711% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -200.095% |
| Pulmatrix, Inc. | 22.03 Million USD | -3916.245% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -2459.942% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -895.994% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -60.47% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -1119.969% |
| Cytokinetics, Incorporated | 173.61 Million USD | -409.815% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -2471.545% |
| Nutriband Inc. | 5.73 Million USD | -15335.912% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -1929.441% |
| Vor Biopharma Inc. | 126.03 Million USD | -602.26% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 25.57% |
| Evogene Ltd. | 27.79 Million USD | -3084.959% |
| ProKidney Corp. | 151.52 Million USD | -484.14% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -1093.259% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -11406.398% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -44.1% |
| CorMedix Inc. | 48.95 Million USD | -1707.884% |
| BioLineRx Ltd. | 50.8 Million USD | -1642.254% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -487.326% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -2224.806% |
| Atai Life Sciences N.V. | 125.78 Million USD | -603.661% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -984.159% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -987.226% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -250.462% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -2603.421% |
| MediciNova, Inc. | 10.9 Million USD | -8019.986% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -587.083% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -12092.259% |
| GeoVax Labs, Inc. | 6.02 Million USD | -14597.353% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -85.805% |
| Biomea Fusion, Inc. | 126.13 Million USD | -601.708% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 32.53% |
| Mereo BioPharma Group plc | 35.84 Million USD | -2369.449% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -363.187% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -284.903% |
| Absci Corporation | 73.66 Million USD | -1101.504% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -3108.977% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -562.55% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -265.499% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -237.763% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -325.541% |
| Allakos Inc. | 196.05 Million USD | -351.453% |
| Imunon, Inc. | 20.31 Million USD | -4257.861% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -680.037% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -140.117% |
| BioAtla, Inc. | 129.68 Million USD | -582.489% |
| NLS Pharmaceutics AG | 11.8 Million USD | -7396.36% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -5486.694% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -942.3% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -2019.594% |
| XOMA Corporation | 46.46 Million USD | -1804.957% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -696.161% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -521.284% |
| aTyr Pharma, Inc. | 12.97 Million USD | -6719.478% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -753.882% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -412.003% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -247.42% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -2266.071% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -10661.338% |
| Akari Therapeutics, Plc | 16.8 Million USD | -5166.571% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -38823.117% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -195.706% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -13054.042% |
| UroGen Pharma Ltd. | 138.88 Million USD | -537.276% |
| Sutro Biopharma, Inc. | 243 Million USD | -264.225% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -12066.955% |
| Orgenesis Inc. | 45.75 Million USD | -1834.349% |
| Entera Bio Ltd. | 8.86 Million USD | -9889.842% |
| GH Research PLC | 41.22 Million USD | -2047.154% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -3342.897% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -965.705% |
| Xencor, Inc. | 306.97 Million USD | -188.328% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -17840.225% |
| Replimune Group, Inc. | 234.77 Million USD | -277.002% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -4219.692% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -361.48% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -13054.042% |
| Portage Biotech Inc. | 18.19 Million USD | -4763.454% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -12092.259% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -743.266% |
| OncoCyte Corporation | 25.63 Million USD | -3352.432% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -14420.293% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -7625.367% |
| Purple Biotech Ltd. | -22.46 Million USD | 4039.556% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -5270.752% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1257.974% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -10371.166% |
| HilleVax, Inc. | 133.34 Million USD | -563.767% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -8505.737% |
| Tharimmune, Inc. | 9.45 Million USD | -9260.967% |
| Genprex, Inc. | 31.06 Million USD | -2749.594% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -371.988% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -2720.856% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -115599.346% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -16149.553% |
| OKYO Pharma Limited | 8243.57 USD | -10736753.087% |
| Savara Inc. | 15.74 Million USD | -5521.467% |
| Curis, Inc. | 58.35 Million USD | -1416.751% |
| Daré Bioscience, Inc. | 33.6 Million USD | -2533.489% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -17280.502% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -11763.021% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -3175.479% |
| BeiGene, Ltd. | 3.28 Billion USD | 73.069% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -4338.972% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -77.458% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -476.042% |
| Erasca, Inc. | 141.52 Million USD | -525.402% |
| bluebird bio, Inc. | 240.23 Million USD | -268.436% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -19451.692% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 49.315% |
| DBV Technologies S.A. | 92.16 Million USD | -860.395% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -19451.692% |
| Moderna, Inc. | 6.39 Billion USD | 86.157% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -1977.261% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -6061.075% |
| Molecular Templates, Inc. | 63.09 Million USD | -1302.894% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1226.967% |
| Travere Therapeutics, Inc. | 472 Million USD | -87.52% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -517.608% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -1325.695% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -1938.743% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -325.263% |
| MacroGenics, Inc. | 217.21 Million USD | -307.476% |
| RenovoRx, Inc. | 11.39 Million USD | -7666.76% |
| Adicet Bio, Inc. | 152.03 Million USD | -482.157% |
| Prime Medicine, Inc. | 186.63 Million USD | -374.231% |
| Aditxt, Inc. | 25.95 Million USD | -3310.689% |
| Adagene Inc. | 41.83 Million USD | -2015.877% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -12007.909% |
| Quantum-Si incorporated | 111.65 Million USD | -692.681% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -415.042% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -5971.574% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -2370.828% |
| SciSparc Ltd. | 9.01 Million USD | -9722.439% |
| Vericel Corporation | 142.04 Million USD | -523.134% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -10124.493% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -3733.495% |
| Generation Bio Co. | 144.46 Million USD | -512.666% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -966.0% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -923.71% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -199.303% |
| Invivyd, Inc. | 205.75 Million USD | -330.172% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -1126.597% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -9337.539% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -1076.15% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -8504.063% |
| 2seventy bio, Inc. | 289.88 Million USD | -205.326% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1229.258% |
| Clene Inc. | 41.07 Million USD | -2054.944% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -6810.586% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -1515.264% |
| GeoVax Labs, Inc. | 6.02 Million USD | -14597.353% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -151.415% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -2309.614% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -2524.229% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -753.503% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -2615.947% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -419.797% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -15.289% |
| Evaxion Biotech A/S | 22.27 Million USD | -3874.405% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -552.998% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -276.828% |
| Trevena, Inc. | 38.41 Million USD | -2204.168% |
| Surrozen, Inc. | 18.55 Million USD | -4671.429% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -1007.136% |
| Cingulate Inc. | 22.75 Million USD | -3788.979% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 11913.935% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -1881.552% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -10649.409% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -763.024% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -17.374% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -1325.879% |
| Clearmind Medicine Inc. | 8.74 Million USD | -10025.438% |
| Kronos Bio, Inc. | 128.11 Million USD | -590.847% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -952.788% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -30077.447% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -777.84% |
| Statera Biopharma, Inc. | 28.82 Million USD | -2970.119% |
| ImmunityBio, Inc. | 362.87 Million USD | -143.915% |
| Korro Bio, Inc. | 84.53 Million USD | -947.034% |
| Kineta, Inc. | 21.15 Million USD | -4083.683% |
| BioVie Inc. | 31.95 Million USD | -2670.248% |
| Codexis, Inc. | 66.51 Million USD | -1230.617% |
| Celularity Inc. | 215.05 Million USD | -311.563% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -290.564% |
| Celcuity Inc. | 66.23 Million USD | -1236.397% |
| Virax Biolabs Group Limited | 6.54 Million USD | -13419.039% |
| Cibus, Inc. | 320.3 Million USD | -176.33% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -1958.372% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -2515.235% |
| IN8bio, Inc. | 30.33 Million USD | -2817.559% |
| Kodiak Sciences Inc. | 277.32 Million USD | -219.161% |
| Annexon, Inc. | 143.72 Million USD | -515.837% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -593.701% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -3763.547% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -138196.875% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -13.534% |
| Eyenovia, Inc. | 25.4 Million USD | -3383.762% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -530.795% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -15813.341% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -1018.497% |
| Arcellx, Inc. | 200.19 Million USD | -342.11% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -1828.322% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -308.99% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -8789.224% |
| Moolec Science SA | 52.75 Million USD | -1577.895% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -1347.708% |
| Geron Corporation | 70.44 Million USD | -1156.513% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -1801.805% |
| Royalty Pharma plc | 862.4 Million USD | -2.632% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -840.875% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -9388.773% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -3811.433% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -325.914% |
| Humacyte, Inc. | 23.49 Million USD | -3666.864% |
| Structure Therapeutics Inc. | 102.77 Million USD | -761.202% |
| 89bio, Inc. | 151.2 Million USD | -485.368% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -1004.552% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -5987.345% |
| Genelux Corporation | 24.33 Million USD | -3537.148% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -2509.144% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -412.006% |
| Notable Labs, Ltd. | 14.77 Million USD | -5892.552% |
| Liquidia Corporation | 87.98 Million USD | -905.978% |
| Mustang Bio, Inc. | 48.5 Million USD | -1724.911% |
| Immunovant, Inc. | 282.7 Million USD | -213.078% |
| Quantum-Si incorporated | 111.65 Million USD | -692.681% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -3826.1% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -4061.847% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -767.643% |
| Acasti Pharma Inc. | 11.3 Million USD | -7732.05% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -3761.507% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -5439.02% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -1801.723% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -77911.246% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -5471.572% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -2935.635% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -2038.749% |
| PepGen Inc. | 84.76 Million USD | -944.169% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -2887.074% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -3765.572% |
| Solid Biosciences Inc. | 104.31 Million USD | -748.488% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -2604.616% |
| Immuneering Corporation | 58.41 Million USD | -1415.248% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -17288.192% |
| Silo Pharma, Inc. | 3.92 Million USD | -22468.396% |
| Belite Bio, Inc | 31.66 Million USD | -2694.935% |
| XOMA Corporation | 46.46 Million USD | -1804.957% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1210.289% |
| Bionomics Limited | 17.89 Billion USD | 95.053% |
| Apogee Therapeutics, Inc. | 93 Million USD | -851.69% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2580.661% |
| uniQure N.V. | 285.08 Million USD | -210.468% |
| Cassava Sciences, Inc. | 105.95 Million USD | -735.339% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -12007.909% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -355.751% |
| Forte Biosciences, Inc. | 32.47 Million USD | -2625.313% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -10552.619% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -2911.056% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -15813.341% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -6128.712% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -9857.251% |
| Altimmune, Inc. | 30.55 Million USD | -2796.649% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -106.968% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 2580.661% |
| Compugen Ltd. | 43.97 Million USD | -1912.918% |
| Peak Bio, Inc. | 1249.13 USD | -70857216.692% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -1094.145% |
| Benitec Biopharma Inc. | 22.38 Million USD | -3854.517% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -263.956% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -3000.935% |
| Zura Bio Limited | 62.63 Million USD | -1313.04% |
| PolyPid Ltd. | 21.04 Million USD | -4105.75% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -5338.068% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -3000.935% |
| Instil Bio, Inc. | 85.78 Million USD | -931.765% |
| argenx SE | 1.53 Billion USD | 42.283% |
| Immunome, Inc. | 122.82 Million USD | -620.648% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -1725.965% |
| Verona Pharma plc | 67.15 Million USD | -1218.069% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -3319.355% |
| Shattuck Labs, Inc. | 93.61 Million USD | -845.478% |
| CervoMed Inc. | 14.95 Million USD | -5817.327% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -1151.856% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -10259.316% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -1635.49% |
| Moolec Science SA | 52.75 Million USD | -1577.895% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -5281.057% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -567.722% |
| AnaptysBio, Inc. | 181.56 Million USD | -387.476% |
| Design Therapeutics, Inc. | 78.19 Million USD | -1031.986% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -916.877% |
| NeurAxis, Inc. | 8.82 Million USD | -9933.783% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -6932.976% |
| Lumos Pharma, Inc. | 38.66 Million USD | -2189.15% |
| Achilles Therapeutics plc | 75.25 Million USD | -1076.134% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -3319.355% |
| 180 Life Sciences Corp. | 13.47 Million USD | -6467.242% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -3239.692% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -30077.447% |
| Nutriband Inc. | 5.73 Million USD | -15335.912% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -698.971% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -1490.39% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -1639.618% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1239.052% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -1535.346% |
| Palisade Bio, Inc. | 13.32 Million USD | -6544.895% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -1849.173% |
| Beam Therapeutics Inc. | 554.19 Million USD | -59.709% |
| Neurogene Inc. | 55.58 Million USD | -1492.393% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -256.193% |
| AEON Biopharma, Inc. | 48.42 Million USD | -1727.624% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -815.21% |
| Sesen Bio, Inc. | 78.38 Million USD | -1029.228% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -959.632% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -6931.916% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -96.256% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -907.054% |
| Athira Pharma, Inc. | 125.46 Million USD | -605.45% |
| Vaccinex, Inc. | 23.45 Million USD | -3673.609% |
| HCW Biologics Inc. | 21.02 Million USD | -4109.246% |
| XOMA Corporation | 46.46 Million USD | -1804.957% |
| Nektar Therapeutics | 190.9 Million USD | -363.639% |
| Arvinas, Inc. | 480 Million USD | -84.396% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -38823.117% |
| Merus N.V. | 200.49 Million USD | -341.46% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -756.369% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -2456.615% |
| Rezolute, Inc. | 70.38 Million USD | -1157.477% |
| Clene Inc. | 41.07 Million USD | -2054.944% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -5304.044% |
| BeyondSpring Inc. | 24.86 Million USD | -3459.622% |
| Synlogic, Inc. | 58.53 Million USD | -1412.164% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -4846.904% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -19603.918% |
| Peak Bio, Inc. | 1249.13 USD | -70857216.692% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -1364.282% |
| Krystal Biotech, Inc. | 160.42 Million USD | -451.719% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -227.05% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -154.311% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -40938.904% |
| MannKind Corporation | 125.59 Million USD | -604.714% |
| Ikena Oncology, Inc. | 84.57 Million USD | -946.502% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -9074.873% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -887.824% |
| Gossamer Bio, Inc. | 183.75 Million USD | -381.663% |
| CohBar, Inc. | 12.38 Million USD | -7044.646% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -1644.933% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -3108.977% |
| Legend Biotech Corporation | 583.14 Million USD | -51.78% |
| Mural Oncology plc | 192.07 Million USD | -360.819% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -1218.153% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -5382.101% |
| Disc Medicine, Inc. | 91.12 Million USD | -871.303% |
| Champions Oncology, Inc. | 28.11 Million USD | -3048.702% |
| REGENXBIO Inc. | 321.15 Million USD | -175.597% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -16409.259% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -1487.452% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -2171.78% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -673.98% |
| Vaxart, Inc. | 90.72 Million USD | -875.575% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -10288.488% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -1968.277% |
| Cellectis S.A. | 97.32 Million USD | -809.474% |
| Longeveron Inc. | 21.25 Million USD | -4065.176% |
| Repare Therapeutics Inc. | 167.35 Million USD | -428.869% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 34.958% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -1070.071% |
| Revolution Medicines, Inc. | 498.76 Million USD | -77.458% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -13205.773% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -1913.696% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -1086.62% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -1171.056% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -7902.712% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 81.464% |
| Denali Therapeutics Inc. | 527.23 Million USD | -67.877% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -10124.493% |
| Veru Inc. | 101.34 Million USD | -773.326% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -3681.347% |
| Cingulate Inc. | 22.75 Million USD | -3788.979% |
| Passage Bio, Inc. | 108.38 Million USD | -716.596% |
| Context Therapeutics Inc. | 25.07 Million USD | -3430.146% |
| Exicure, Inc. | 14.07 Million USD | -6188.008% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -329.527% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -1944.064% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -9544.459% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -250.558% |
| Nuvalent, Inc. | 149.49 Million USD | -492.072% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -10871.994% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -753.932% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -4026.533% |
| OmniAb, Inc. | 83.89 Million USD | -955.009% |
| Anew Medical, Inc. | 1.3 Million USD | -67940.598% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -2601.441% |
| Lipocine Inc. | 15.08 Million USD | -5769.309% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1191.872% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -1062.281% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2095.498% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -670.704% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -3854.164% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -33.269% |
| Ocugen, Inc. | 71.56 Million USD | -1136.743% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -842.94% |
| Q32 Bio Inc. | 92.68 Million USD | -855.006% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -4080.127% |
| Alumis Inc. Common Stock | 158.17 Million USD | -459.574% |
| Equillium, Inc. | 50.6 Million USD | -1649.002% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -1318.293% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -6265.082% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -4591.73% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -1785.157% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -716.016% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -7042.092% |
| Dominari Holdings Inc. | 23.83 Million USD | -3613.447% |
| Edesa Biotech, Inc. | 9.22 Million USD | -9496.912% |
| vTv Therapeutics Inc. | 11.9 Million USD | -7333.443% |
| Bio-Techne Corporation | 563.03 Million USD | -57.2% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -116.509% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -229.332% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -569.126% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -6041.836% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -440.697% |
| Nkarta, Inc. | 131.65 Million USD | -572.313% |
| BioCardia, Inc. | 12.12 Million USD | -7202.203% |
| Iterum Therapeutics plc | 47.46 Million USD | -1764.625% |